CN113166137B - O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 - Google Patents

O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 Download PDF

Info

Publication number
CN113166137B
CN113166137B CN201980060829.1A CN201980060829A CN113166137B CN 113166137 B CN113166137 B CN 113166137B CN 201980060829 A CN201980060829 A CN 201980060829A CN 113166137 B CN113166137 B CN 113166137B
Authority
CN
China
Prior art keywords
methyl
acetamide
oxy
thiazol
methylpyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060829.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166137A (zh
Inventor
N.杰农
K.M.古基安
J.韦塞尔斯
L.张
R.吉亚纳塔西奥
E.Y.S.林
Z.辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to CN202411009108.7A priority Critical patent/CN119219621A/zh
Publication of CN113166137A publication Critical patent/CN113166137A/zh
Application granted granted Critical
Publication of CN113166137B publication Critical patent/CN113166137B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CN201980060829.1A 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 Active CN113166137B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411009108.7A CN119219621A (zh) 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US62/733,484 2018-09-19
US201862750000P 2018-10-24 2018-10-24
US62/750,000 2018-10-24
PCT/US2019/051661 WO2020061150A1 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411009108.7A Division CN119219621A (zh) 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Publications (2)

Publication Number Publication Date
CN113166137A CN113166137A (zh) 2021-07-23
CN113166137B true CN113166137B (zh) 2024-08-16

Family

ID=68073263

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980060829.1A Active CN113166137B (zh) 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
CN202411009108.7A Pending CN119219621A (zh) 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411009108.7A Pending CN119219621A (zh) 2018-09-19 2019-09-18 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Country Status (22)

Country Link
US (2) US12180205B2 (cg-RX-API-DMAC7.html)
EP (1) EP3853226A1 (cg-RX-API-DMAC7.html)
JP (2) JP7606960B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210060513A (cg-RX-API-DMAC7.html)
CN (2) CN113166137B (cg-RX-API-DMAC7.html)
AU (1) AU2019344922B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004739A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113009A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000646A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004873A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210181A (cg-RX-API-DMAC7.html)
IL (2) IL315564A (cg-RX-API-DMAC7.html)
JO (1) JOP20210036A1 (cg-RX-API-DMAC7.html)
MA (1) MA53648A (cg-RX-API-DMAC7.html)
MX (1) MX2021003232A (cg-RX-API-DMAC7.html)
PE (1) PE20211591A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550439A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102379XA (cg-RX-API-DMAC7.html)
TW (1) TWI863926B (cg-RX-API-DMAC7.html)
UA (1) UA130690C2 (cg-RX-API-DMAC7.html)
UY (1) UY38376A (cg-RX-API-DMAC7.html)
WO (1) WO2020061150A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
AR123132A1 (es) * 2020-08-03 2022-11-02 Biogen Ma Inc Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
KR102533471B1 (ko) 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease
WO2026112144A1 (en) 2024-11-20 2026-05-28 Dewpoint Therapeutics, Inc. Modulators of beta catenin and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109202A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ グループ リミテッド Ldl−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013170072A2 (en) 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
EP2914604A4 (en) 2012-10-31 2016-07-20 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
WO2014159234A1 (en) * 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
EP3555094A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Bicyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-甲基-1,2,4-二唑-3-基化合物
EP3765458B1 (en) * 2018-03-14 2023-01-11 Biogen MA Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
WO2019243531A1 (en) 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
CN113166137B (zh) 2018-09-19 2024-08-16 比奥根Ma公司 O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109202A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds

Also Published As

Publication number Publication date
TW202031651A (zh) 2020-09-01
IL281514B2 (en) 2025-02-01
US20240308995A1 (en) 2024-09-19
CN113166137A (zh) 2021-07-23
IL281514B1 (en) 2024-10-01
KR20210060513A (ko) 2021-05-26
JP7606960B2 (ja) 2024-12-26
AU2019344922A1 (en) 2021-03-25
UY38376A (es) 2020-04-30
JP2025011144A (ja) 2025-01-23
BR112021004739A2 (pt) 2021-06-01
EP3853226A1 (en) 2021-07-28
CL2021000646A1 (es) 2021-09-03
CA3113009A1 (en) 2020-03-26
SG11202102379XA (en) 2021-04-29
US12275728B2 (en) 2025-04-15
CR20210181A (es) 2021-07-01
US12180205B2 (en) 2024-12-31
UA130690C2 (uk) 2026-04-22
JP2022500472A (ja) 2022-01-04
TWI863926B (zh) 2024-12-01
MX2021003232A (es) 2021-07-16
AU2019344922B2 (en) 2025-02-06
US20220041586A1 (en) 2022-02-10
MA53648A (fr) 2021-07-28
PE20211591A1 (es) 2021-08-18
WO2020061150A1 (en) 2020-03-26
IL315564A (en) 2024-11-01
CN119219621A (zh) 2024-12-31
PH12021550439A1 (en) 2021-11-29
IL281514A (en) 2021-04-29
JOP20210036A1 (ar) 2021-02-25
CO2021004873A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
CN119219621A (zh) O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
US11129832B2 (en) Biheteroaryl compounds and uses thereof
CN112218863B (zh) O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂
EP2852584B1 (en) Substituted dipyridylamines and uses thereof
US20230121086A1 (en) RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF
WO2018066718A1 (en) Therapeutic compounds
CA3099863A1 (en) Furin inhibitors
KR102920418B1 (ko) 키나아제 억제 활성을 갖는 화합물
KR102920599B1 (ko) 항종양 활성을 갖는 화합물 및 이의 용도
CN111247135A (zh) 嘧啶ΤΒΚ/ΙΚΚε抑制剂化合物及其用途
WO2020011147A1 (en) RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE
KR20230160901A (ko) 유비퀴틴 특이 프로테아제 19(usp19)의 억제제로서의 약제학적 화합물
EP4709370A2 (en) Stat degraders and uses thereof
CN103221405B (zh) 取代的吡啶化合物
EP3789378A1 (en) Piperidines or piperidones substituted with urea and heteroaryl

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant